Clinical malaria incidence · people living in malaria‐endemic areas
It is very uncertain whether ivermectin changes incidence of clinical malaria compared with control (very low certainty).
1 finding from 1 review
no estimate extracted
590 participants
Very low
Adverse events · people living in malaria‐endemic areas
It is very uncertain whether ivermectin changes adverse events compared with control (very low certainty).
1 finding from 1 review
RR 1.63 [1, 2.67]
2712 participants
Very low
Complete clearance · people with scabies, over 5 years of ageLocation: India
Oral ivermectin 200 μg/kg (1 dose) showed no clear difference in complete clearance ‐ week 4 compared with oral ivermectin 200 μg/kg (2 doses) (high certainty).
1 finding from 1 review
1Sharma 2011. · people with scabies, over 5 years of ageLocation: India
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Complete clearance · people with scabies, 5 to 80 years of ageLocation: Egypt, India
Oral ivermectin 200 μg/kg (1 to 3 doses) showed no clear difference in complete clearance ‐ week 1 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (low certainty).
3 findings from 1 review
RR 0.84 [0.65, 1.08]
1 study · 62 participants
Low
RR 1 [0.94, 1.06]
1 study · 62 participants
Moderate
RR 0.99 [0.95, 1.03]
2 studies · 272 participants
Moderate
Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: Egypt, India
It is very uncertain whether oral ivermectin 200 μg/kg (1 to 3 doses) changes number of participants with ≥ 1 AE ‐ week 4 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with scabies, 5 to 80 years of ageLocation: Egypt, India
1 finding from 1 review
HRQOL DLQI and RosaQoL · Participants with rosacea
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
QoL · Participants with rosacea
Topical ivermectin leads to higher HRQOL DLQI, proportion of participants that reported at end of study… compared with topical metronidazole (high certainty).
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
Topical ivermectin leads to higher participant‐assessed improvement in rosacea severity Likert scale ‐… compared with topical metronidazole (high certainty).
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Topical ivermectin showed no clear difference in proportion of participants with adverse event compared with topical metronidazole (moderate certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
Topical ivermectin leads to higher physician‐assessed improvement in rosacea severity compared with topical metronidazole (high certainty).
1 finding from 1 review
Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review